I sent an email to Imagion this morning querying the R&D Tax Incentive payments going forward.
Geoff Hollis responded by email promptly.
Apparently, the incentive has been assessed on local and USA R&D costs incurred by the company.
In response to my query, Geoff advised that, with the Phase 1 trial now completed, the company will be unable to claim costs for its US R&D after 2023 (as I understand it).
Shareholders and potential investors may wish to exercise caution when reading the company's Quarterley Activity Report for the September quarter. Para 8 of that Report is headed "Estimated cash available for future operating activities". It incorporates the full amount of the R&D Tax Incentive going forward.
Geoff said that they have been aware of the issue and intend to update the market.
This is not investment advice and please do your own research.
Regards Stretguy
IBX Price at posting:
1.1¢ Sentiment: Sell Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)